EXACT THERAPEUTICS TO PRESENT AT PARETO SECURITIES 12th ANNUAL HEALTHCARE CONFERENCE
OSLO/ LONDON, 31 AUGUST, 2021
Exact Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision medicine company evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that its Chief Executive Officer, Dr Rafiq Hasan, will be presenting at the Pareto Securities 12th Annual Healthcare Conference on Wednesday, 1 September at 12.00pm CET.
For more information, please contact:
Dr Rafiq Hasan
CEO Exact Therapeutics
Email: Rafiq@exact-tx.com
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
Tel: +44 (0) 203 922 1906
Email: Exact@optimumcomms.com
About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
About ACT®
ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.